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Worldwide, the use of Extracorporeal Membrane Oxygenation (ECMO) for cardiac failure
has been steadily increasing in the neonatal population and has become a widely
accepted modality. Especially in centers caring for children with (congenital) heart
disease, ECMO is now an essential part of care available for those with severe heart failure
as a bridge to recovery, long term mechanical support, or transplantation. Short-term
outcomes depend very much on indication. Hospital survival is ∼40% for all neonatal
cardiac ECMO patients combined. ECMO is being used for pre- and/or post-operative
stabilization in neonates with congenital heart disease and in neonates with medical
heart disease such as myocarditis, cardiomyopathy or refractory arrhythmias. ECMO
use during resuscitation (ECPR) or for sepsis is summarized elsewhere in this special
edition of Frontiers in Pediatrics. In this review article, we will discuss the indications for
neonatal cardiac ECMO, the difficult process of patients’ selection and identifying the
right timing to initiate ECMO, as well as outline pros and cons for peripheral vs. central
cannulation. We will present predictors of mortality and, very importantly, predictors of
survival: what can be done to improve the outcomes for your patients. Furthermore,
an overview of current insights regarding supportive care in neonatal cardiac ECMO
is given. Additionally, we will address issues specific to neonates with single ventricle
physiology on ECMO, for example cannulation strategies and the influence of shunt type
(Blalock-Taussig shunt vs. “right ventricle to pulmonary artery” shunt). We will not only
focus on short term outcomes, such as hospital survival, but also on the importance of
long-term neuro-developmental outcomes, and we will end this review with suggestions
for future research.
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INTRODUCTION
Since the inception of Extracorporeal Membrane Oxygenation (ECMO), the number of annually
performed ECMO runs for neonates with cardiac disease has been steadily increasing (1)
(Figure 1). In the last decade, ∼400–500 neonates have been supported with ECMO each year in
centers reporting to the Extracorporeal Life Support Organization (ELSO). Since 1987, more than
8,000 neonates have been registered in the ELSO database (1). Hospital survival is∼40% and hasn’t
really changed since 1987, despite increased experience, better equipment and enforced education
and team training. This might be due to a constant widening of indications, increasing levels of
complexity and acuity (2, 3).
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FIGURE 1 | ELSO data report 2019 (1).
In hospitals caring for children with heart disease, ECMO has
become an essential part of modalities available to temporarily
support these neonates when conventional therapy fails. ECMO,
however is not a treatment in itself. The goal of ECMO
support is to offer the failing myocardium a chance to recover
while the body is provided with adequate blood supply.
Most often, ECMO for neonatal cardiac disease is used as a
bridge to recovery, bridge to long-term support, as a bridge
to heart transplantation or bridge to decision making (e.g.,
diagnostic work-up, organ donor). However, ECMO is no
longer a rescue treatment per se, as it has also found its
way as elective support during diagnostic and therapeutic
procedures (4).
In this review article, we will discuss the indications for
neonatal cardiac ECMO, the difficult process of patients’
selection, identifying the right timing to initiate ECMO, and
outline pros and cons for peripheral vs. central cannulation.
We will present predictors of mortality and, very importantly,
predictors of survival: what can be done to improve the outcomes
for your patients. It is essential that explanations are sought
for the circulatory compromise leading to ECMO, so attempts
can be made to correct possible reversible diseases, such as
residual lesions following congenital heart surgery. It is also
extremely important to decompress the heart as much as
possible to decrease myocardial work and oxygen consumption
aiding in recovery. Furthermore, an overview of current insights
regarding supportive care in neonatal cardiac ECMO is given.
Additionally, we will address issues specific to neonates with
single ventricle physiology on ECMO, for example cannulation
strategies and the influence of shunt type (Blalock-Taussig shunt
vs. “right ventricle to pulmonary artery” shunt). We will not
only focus on short-term outcomes, such as hospital survival, but
also address the importance of long-term neuro-developmental
outcomes and we will end this review with suggestions for
future research.
INDICATIONS
Neonates receiving ECMO for cardiac disease constitute a
heterogenous group and can receive ECMO for surgical or
medical cardiac disease, such as cardiomyopathy, myocarditis,
and/or arrhythmias (Table 1).
Congenital Heart Disease
In neonates with surgical cardiac disease, ECMO can be
utilized for pre-operative stabilization (e.g., transposition of
the great arteries with pulmonary hypertension), failure to
wean from cardiopulmonary bypass (CPB), or low cardiac
output syndrome (LCOS) post-operatively. Following congenital
heart surgery, ECMO is utilized in 1.4–5% of operations
(5–7). Cardiac arrest as an indication for ECMO is called
Extracorporeal Cardiopulmonary Resuscitation (ECPR) and
is discussed elsewhere in this Research Topic of Frontiers
in Pediatrics.
According to a recent Society of Thoracic Surgeons (STS)-
database study, risk factors for receiving post-operative ECMO
include young age (13 vs. 195 days), low weight (3.4 vs. 6.4 kg),
mechanical ventilation prior to surgery (37 vs. 15% chance of
receiving ECMO), arrhythmia (4.6 vs. 2.6%), shock (7.4 vs.
1.7%), higher complexity as indicated by ‘STAT’ category of 4–
5 (72 vs. 34%), and CPB-duration (175 vs. 94min) (5). Also,
more complex lesions have a higher chance of receiving ECMO
post-operatively. For instance, in neonates following Norwood
operations, incidence of ECMO is much higher with ∼13% of
neonates receivingmechanical support post-operatively (8). Also,
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TABLE 1 | Neonatal cardiac runs by diagnosis in the last five years (2014–2019),








Congenital defect 1,487 144 1,481 698 46%
Cardiac arrest 15 157 600 6 40%
Cardiogenic shock 77 153 1,746 43 55%
Cardiomyopathy 27 231 848 15 55%
Myocarditis 25 250 628 13 52%
Other 621 168 3,737 342 55%
Avg, average. Run times are given in hours.
TABLE 2 | Risk factors for receiving ECMO following neonatal heart surgery.
Risk factors for receiving post-cardiotomy ECMO
Young age STAT category 4–5
Lower weight CPB duration
Mechanical ventilation pre-operative –
Arrhythmia Shock
Higher vasoactive-inotropic score (VIS) –
STAT, Society of Thoracic surgeons—European Association for cardio-Thoracic surgery;
CPB, cardiopulmonary bypass.
higher Vasoactive-inotropic scores have been associated with
increased ECMO utilization (9) (Table 2).
Myocarditis/Cardiomyopathy
The incidence of myocarditis in neonates is not clearly known
because the diagnosis remains challenging due to non-specific
symptoms, often masquerading as respiratory or gastrointestinal
infection. In 2017, a group from Finland analyzed the occurrence
and features of childhood Myocarditis and found an incidence
of 1.95/100,000 person-years (10). Interestingly, two peaks in
occurrence were noted: in infants <1 year and in teenagers.
Myocarditis in newborns is mainly caused by viral infection, such
as enterovirus, parvovirus, or adenovirus (11).
Looking at the ELSO data registry, out of 2,252 neonatal
cardiac runs (2014–2018), myocarditis was listed in only 25 cases
as the reason for ECMO initiation (1). A recently published
article from Melbourne described a series of seven neonatal
myocarditis cases requiring ECMO due to Enterovirus infection
(12). In this article, Cortina et al. also included 35 cases of
Enterovirus Myocarditis supported with ECMO from literature
review in their data analysis. The survival rate of all those cases
together was 36% (15/42), which is lower than survival (to
discharge or transfer) reported in the ELSO registry with 52% for
this population (12).
Extracorporeal Membrane Oxygenation (ECMO) support for
neonatal myocarditis is infrequent and still carries a high risk of
complications and death, but in some cases can lead to complete
cardiac recovery with favorable long-term outcome. But who
would benefit from ECMO support and when to initiate it?
Casadonte et al. investigated risk factors for cardiac arrest
or mechanical support (MCS) in children with fulminate
myocarditis (13). The average age of the 28 patients in this
study was 1.2 years (1 day−17 years), but no subgroup of
true neonates was analyzed. They found that patients in the
CPR/MCS group had higher peak b-type natriuretic peptide
(BNP) and peak inotropic score. Unfortunately, there was no
marker on admission identified, which could be used as a
prediction tool. Other authors found associations between the
need for MCS and significant arrhythmias or evidence of end
organ dysfunction (14, 15).
Neonates with fulminate myocarditis are at risk for
cardiovascular collapse leading to CPR and/or MCS.
Unfortunately, no clinical variables predict the probability
of MCS or the outcome. In children, ECMO has been
shown to improve survival for circulatory collapse due to
arrhythmias in myocarditis (16). Further collaboration and
research in this field is needed to shed some light on the
unknown elements.
A recent meta-analysis of myocarditis and ECMO described
a 54–83% long-term survival with optimistic quality of life (17).
The analysis included six studies, and all used slightly different
criteria for initiation of ECMO, but the authors concluded that
a systolic BP < 50 mmHg for neonates despite >2 inotropes or
high inotrope score could be a reasonable threshold.
Arrhythmias
Neonatal arrhythmias can occur post-operatively (e.g., atrial
tachycardia, junctional ectopic tachycardia, ventricular
tachycardia, or complete heart block), as part of
myocarditis/cardiomyopathy as discussed above, or as a
primary arrhythmia (e.g., re-entry supraventricular tachycardia
or Brugada syndrome). If the arrhythmia leads to refractory
shock despite pharmacological treatment, ECMO can be
indicated (18–20). During ECMO support, pharmacological
treatment can be optimized, cardiac catheterization with possible
ablation of accessory pathways can be performed, or a pacemaker
can be implanted. For total AV-block, a pacemaker can be placed
while supported with ECMO. The utilization of ECMO for
arrhythmias is rare but carries very good survival and neurologic
outcomes (21).
Pulmonary Hypertension
The indication of ECMO for persistent pulmonary hypertension
of the newborn associated with diaphragmatic hernia, meconium
aspiration, respiratory distress syndrome, or sepsis is beyond
the scope of this review. In a large database study of neonates
and children with pulmonary artery hypertension, 1.4% received
ECMO with a hospital mortality of 39% and significant
complications (22). ECMO for pulmonary hypertension
associated with congenital heart disease has good outcomes
(23, 24). Said et al. reported the example of pulmonary
hypertension associated with transposition of the great
arteries (25). Pulmonary hypertension following cardiac
surgery is often due to temporarily increased pulmonary
vascular resistance because of cardiopulmonary bypass
and probably has better ECMO survival than pulmonary
artery hypertension.
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TABLE 3 | Hospital survival based on location of ECMO initiation in either operation room (OR) because of failure to wean from bypass or in the intensive care unit (ICU)
due to low cardiac output syndrome or hypoxia (7, 26–30).
Hospital survival (%)
Population Overall survival OR ICU Statistical significance
Jaggers et al. (26) N = 35 (median age 19 days) 60 60 60 NS
Kolovos et al. (27) N = 74 (median age 17 days) 50 64 41 P = 0.06
Chaturvedi et al. (28) N = 81 children (median age 2.4 months) 49 64 29 P = 0.003
Sasaki et al. (7) N = 36 (median age 64 days) 47 43 60 NS
Casadonte et al. (13) N = 90 (age 6–912 days) 73 77 62 NS
Khorsandi et al. (30) N = 66 Age < 16 years 44 47 38 NS
TABLE 4 | Indications to cardiac ECMO according to the ELSO guidelines (33).
Use of extracorporeal life support for cardiac failure should be
considered for patients with evidence of inadequate end organ perfusion
and oxygen delivery resulting from inadequate systemic cardiac output
(a) Hypotension despite maximum doses of two inotropic or vasopressor
medications.
(b) Low cardiac output with evidence of end organ malperfusion despite medical
support as described above: persistent oliguria, diminished peripheral pulses.
(c) Low cardiac output with mixed venous, or superior caval central venous (for
single ventricle patients) oxygen saturation <50% despite maximal medical
support.
(d) Low cardiac output with persistent lactate >4.0 mmol/l and persistent upward
trend despite optimization of volume status and maximal medical management.
TIMING—WHEN TO INITIATE ECMO?
In neonates following congenital heart surgery, ECMO can be
initiated in the operating room for failure to separate from
cardiopulmonary bypass or in intensive care for either LCOS
resistant to maximal medical therapy or hypoxia. Reports in the
literature vary (see Table 3), and unfortunately offer not enough
guidance as to the optimal timing of ECMO initiation. Although
it might be logical to assume that earlier support may lead
to better outcomes, neonates who fail to separate from bypass
might be sicker and have worse myocardial depression than
those that do separate from CPB and then develop worsening
of LCOS although there is no data to support this hypothesis.
Earlier reports suggested that failure to separate from CPB
was a risk factor for increased mortality (27, 28). However, a
recent ELSO database study among more than 4,000 neonates
with congenital and acquired heart disease suggests that earlier
initiation of ECMO may reduce mortality due to a decreased
degree and duration of acidosis prior to ECMO. The authors
hypothesized that acidosis probably reflected poor cardiac output
and tissue hypoperfusion and that delayed use of ECMO may
result in prolonged exposure of the myocardium and end-organs
to reduced oxygen delivery resulting in severe or permanent
myocardial or end-organ injury and reduced survival (31).
But in a recent large retrospective study longer time between
surgery and ECMO initiation was not associated with higher
mortality although it was associated with longer ECMOduration,
prolonged length of ventilation, and prolonged length of ICU and
hospital stay (32).
Timing to initiate ECMO therefore remains very difficult.
There are no definitive cut-off points and no evidence-based
guidelines exist as to when to initiate ECMO post-operatively.
The decision to proceed to ECMO cannulation is typically made
on a case-to case basis based on the experience and judgment
of the multidisciplinary team, which is reflected by a substantial
variation in the use of mechanical support across hospitals
(5, 30, 32). The ELSO advises to consider ECMO for patients
with evidence of inadequate end organ perfusion and oxygen
delivery resulting from inadequate systemic cardiac output (see
Table 4) (33).
CONTRAINDICATIONS
The number of contraindications has decreased over recent
years as experience and technology have advanced. The most
important contraindication is lack of possible myocardial
recovery and/or contraindications to heart transplantation. The
ELSO guidelines list absolute and relative contraindications
(Table 5). The absolute contraindications have an inappropriate
chance of major complications and poor outcome, and therefore
ECMO should not be considered in those patients. The relative
contraindications also carry a high risk of poor prognosis,
but careful management may lead to acceptable outcomes. But
parents and the medical team involved should all be aware of the




Due to the size of the neonatal patients, cannulation for cardiac
neonatal VA-ECMO can be done two ways:
1. Peripheral cannulation: drainage via jugular vein and return
via the carotid artery. The right side is the side of choice, but
the left side is also possible.
2. Central cannulation: with chest opening and drainage directly
out of the right atrium and return into the aortic arch.
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TABLE 5 | Contraindications to cardiac ECMO according to the ELSO guidelines
(33).
Use of ECLS is not recommended under certain circumstances,
particularly if there is strong evidence for lack of capacity to recover or
be treated
1. Cardiopulmonary extracorporeal life support is inappropriate if
(a) The condition is irreversible and/or,
(b) There is no timely, reasonable therapeutic option and/or,
(c) High likelihood of poor neurological outcome.
2. Absolute contraindications: Extracorporeal life support is not
recommended in the following circumstances
(a) Extremes of prematurity or low birth weight (<30 weeks gestational age or
<1 kg)
(b) Lethal chromosomal abnormalities (e.g., Trisomy 13 or 18)
(c) Uncontrollable hemorrhage
(d) Irreversible brain damage
3. Relative contraindications
(a) Intracranial hemorrhage
(b) Less extreme prematurity or low birth weight in neonates (<34 week
gestational age or <2.0 kg)
(c) Irreversible organ failure in a patient ineligible for transplantation
(d) Prolonged intubation and mechanical ventilation (>2 week) prior to ECLS
Regardless which way is selected, the adequate size of the
cannulas (drainage and return) is crucial to be able to achieve
the desired ECMO flow (100–150 ml/kg/min or 3 l/m2/min).
Every cannula has a pressure/flow chart which describes its
characteristics, so the selection is easily facilitated. Most often,
the largest possible cannula is inserted.
Cannulation via right carotid artery provides very good
hemodynamic support, with flow to the upper body and the
descending aorta, though blood flow of the right cerebral
hemisphere depends on an unhindered circle of Willis.
Neurological complications (such as intracranial hemorrhage,
derangement of cerebral autoregulation, impairment of venous
drainage and risk of embolic events) are well-described in this
population (34, 35).
Other problems reported with this type of peripheral
cannulation approach are dissection of the aorta or carotid
artery (36). Early recognition and timely intervention to those
complications are critical, and serial Echocardiograms should
be provided to detect problems. For further clarification CT
angiogram or catheter investigations can be helpful to identify
the problem.
In some cases, the desired flow cannot be achieved via
the neck cannulation, so the central route is chosen, and for
inability to wean from cardiopulmonary bypass, the simple
conversion to central ECMO is obvious (37). When converting
CPB to ECMO, one should be aware that the arterial CPB
cannula might not be large enough to support a normothermic
patient for several days, especially if sepsis should develop.
Complications of central cannulation include bleeding, vessel
injury and embolic phenomena. A recent case report alluded
to the occurrence of thrombus in the aorta (38). The cannula
inserted in the aorta increases the afterload of the ventricle.
TABLE 6 | Hospital survival of neonatal cardiac ECMO by congenital diagnosis.
Congenital lesion Number of runs Survival (%)
Left to right shunt 92 45
Left-sided obstructive lesion 87 47
Hypoplastic left heart syndrome 439 43
Right-sided obstructive lesion 52 40
Cyanotic—increased Qp 73 43
Cyanotic—pulmonary congestion 167 47
Cyanotic—decreased Qp 295 50
Other 282 51
Qp, pulmonary blood flow (1).
Thrombosis can occur as a result of stasis within the aorta due to
competing flows from the poorly ejecting native ventricle and the
ECLS circuit.
Overall cannulation approaches for neonatal VA ECMO have
not changed over decades, and unfortunately complications rates
remain the same (1).
PREDICTORS OF SURVIVAL
Survival depends very much on the underlying reason for
receiving ECMO support. Overall survival is higher in non-
surgical heart disease such as myocarditis or cardiomyopathy
(see Table 1). In neonates with congenital lesions, the risk factors
of requiring ECMO post-operatively are listed in Table 2 and
are especially high following neonatal Ross-Konno repair [Odds
Ratio (OR) 70], Truncus arteriosus repair (OR 42), arterial
switch operation with VSD (OR 35), ALCPA-repair (OR 20),
TAPVD repair (OR 18), or Norwood operation (OR 9) (5). And
subsequently, mortality during ECMO is also very dependent on
underlying diagnosis and type of operation. According to the
STS database, mortality following Ross-Konno repair or Truncus
repair is ∼70%, whereas mortality for ECMO following ALCPA
repair is only 14% (5). In neonates with ECMO for congenital
heart disease reported to ELSO, survival is between 40 and 51%
(see Table 6).
Many outcome predictors have been identified in the literature
and are presented in Table 7 (7, 8, 23, 31, 39–45). Some
predictors cannot be modified before or during ECMO, such as
age, weight, the presence of chromosomal abnormalities, or the
underlying diagnoses. Other predictors are determined by the
pre-ECMO clinical course, such as inotrope score, duration of
ventilation, presence of fluid overload, and CPR requirement.
These predictors could possibly be influenced by early timing of
ECMO initiation before these predictors occur.
Risk factors for poor outcome that may be modifiable during
ECMO support include the identification of residual lesions,
optimizing systemic perfusion (reflected for instance by clearance
of acidosis), presence of renal failure, and fluid overload, and
the duration of ECMO. As mentioned before, it is essential to
determine the reason the patient requires ECMO support, and
to provide optimal systemic perfusion while resting the heart as
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TABLE 7 | Predictors of mortality and survival of neonatal and pediatric cardiac
ECMO (7, 8, 23, 31, 39–45).
Predictors of mortality
Higher mortality Lower mortality
Younger age
Low bodyweight (<3 kg) Bodyweight >3.3 kg
Chromosomal abnormalities No chromosomal abnormalities
Congenital heart disease Myocarditis/cardiomyopathy
Single-ventricle physiology Two-ventricles
High inotrope score Low inotrope score
Duration of ventilation pre-ECMO >14
days
Duration of ventilation pre-ECMO
<14 days
CPR pre-ECMO No CPR pre-ECMO
Acidosis pre-ECMO (pH < 7.26) No acidosis (pH > 7.28)
High Lactate pre-ECMO Low lactate pre-ECMO
Failure to clear lactate <24 h Able to clear lactate <24 h
Renal failure No renal failure
Fluid overload on ECMO initiation No fluid overload
Organ system complications No organ system complications
Bleeding during ECMO No bleeding
Cardiac catheterization on ECMO <48 h Late or no cardiac catheterization
Duration of ECMO support >7 days Duration of ECMO support <5 days
much as possible and limiting the duration of ECMO support and
concomitant complications which can impact outcomes.
Residual Lesions
Recently, several studies have shown the importance of early
catheterization aimed at identifying and treating residual lesions
(43, 44, 46, 47). In a retrospective study by Agarwal et al.,
residual lesions were present in approximately one-quarter of
post-operative cardiac surgery patients receiving ECMO support
(43). They conclude that all post-operative pediatric cardiac
surgery patients unable to be weaned off ECMO successfully,
should be evaluated actively for residual lesions, preferably
by cardiac catheterization, as echocardiography only detected
20% of all residual lesions and catheterization the remaining
80%. Furthermore, earlier detection (within 3 days of ECMO
support) and reintervention are associated with improved clinical
outcome. In another retrospective study of 84 neonates requiring
ECMO following cardiac surgery, as many as 83% had residual
lesions (44). Time to identification and/or correction of these
residual lesions was significantly shorter in survivors than in non-
survivors (1 vs. 2 days). Abraham et al. catheterized 35 neonates
while on ECMO support, which led to direct intervention in
∼75%, significantly improving survival (46). The average interval
from ECMO cannulation to catheterization was significantly
shorter in survivors (1.6 days) vs. non-survivors (3.5 days). In a
retrospective study by Kato et al., patients who received cardiac
catheterization within 48 h after ECMO initiation demonstrated
significantly better survival than those who underwent later
catheterization (47).
Results of these studies clearly indicate that an early (<24 h)
and proactive search for residual lesions is warranted to improve
survival. Cardiac catheterization can be safely performed on
patients supported by ECMO, and is a critical tool in the early
recognition, diagnosis, and direct treatment of hemodynamic
and/or anatomic abnormalities (48).
Clearance of Acidosis
Providing adequate systemic blood flow is an integral aspect of
ECMO support. If ECMO flow is inadequate, lactate will remain
high as a sign of end-organ hypoperfusion and multiple organ
failure may develop impacting on outcomes (44). Therefore,
aiming to normalize lactate levels as soon as possible (12–24 h
post-cannulation) may improve outcomes. Lactate which has
not normalized within 72 h has been associated with decreased
survival (44).
Renal Failure and Fluid Overload
Renal failure and fluid overload at ECMO initiation have been
identified as risk factors for poor outcomes in multiple studies
(49). Acute kidney injury is probably a reflection of pre-ECMO
injury but could also be due to insufficient ECMO flow. Fluid
overload, with or without renal failure, may impact on respiratory
mechanics and myocardial recovery (49, 50). Renal replacement
therapy during ECMO is therefore advocated by ELSO, and has
been shown to improve fluid balance and electrolytes (51–54).
Renal replacement therapy however does not seem to shorten
ECMO duration or ICU length of stay, nor to improve survival
(51). It is probably best to prevent the development of renal
failure and/or fluid overload prior to initiating ECMO rather than
attempting fluid removal while on ECMO.
Unloading the Ventricle
The goal of cardiac ECMO is to rest the myocardium as
much as possible so it may recover as soon as possible.
However, by increasing the afterload of the systemic ventricle
by placing an arterial ECMO cannula in the aorta or carotid
artery, the already failing myocardium may struggle to eject
blood against this increased afterload, and a cardiac stun may
occur. The aortic valve remains closed and the left ventricle
dilates, because on ECMO there is always blood returning to
the left atrium from Thebesian and bronchial veins. While
dilated, the myocardium stretches and is under strain, therefore
diminishing the coronary perfusion and further impacting on
myocardial recovery. Also, intracavitary thrombus formation
and pulmonary oedema will occur when left atrial pressure
exceeds 25–30mmHg. Echocardiography is essential in assessing
LV distension and presence of spontaneous contrast (55). To
provide optimal myocardial recovery, attempts should be made
to prevent dilatation of the left side of the heart. The right-side
is decompressed by the ECMO circuit. And in lesions affecting
RV dysfunction such as pulmonary hypertension or following
pulmonary atresia repair, unloading the left ventricle is probably
not necessary. In some neonates with LV dysfunction, it may be
enough to support the systemic ventricle with a low dose inotrope
to open the aortic valve and eject just enough blood to prevent
or treat ventricular dilatation. However, in most neonates, this
course of action will not be sufficient, and other steps will have
to be made. A solution is to unload the left side of the heart by
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either creating an atrial shunt via percutaneous atrial septostomy
or surgical atrial septectomy, or by placing an extra ECMO
cannula in the left atrium which drains blood to the inlet side
of the ECMO circuit (the so called “left vent”). In neonates, it
is not known which form of ventricular unloading is preferred,
or what the best timing of unloading is. Currently, there are no
standardized diagnostic criteria or guidelines for the type and
timing of intervention for LV overload (56). Tentatively, left
ventricular unloading should be performed with significant LV
distension or spontaneous contrast on echocardiography, when
the aortic valve does not open, or with signs of pulmonary
oedema on chest x-ray (55, 57).
Elective decompression has been shown to decrease ECMO
duration in pediatric cardiac ECMO patients, but not mortality
(58). In a single center study from Boston, percutaneous atrial
septostomy was used in 10% of all ECMO patients and in 50% of
myocarditis patients (57). Residual atrial septal defects requiring
closure occurred in only a few cases.
ECMO Duration
Duration of ECMO support is another important factor and
has been associated with decreased survival in several studies
(8). With longer ECMO duration, more complications such
as renal failure, bleeding, thrombosis, or infection may occur
which impact survival. Prolonged ECMO in children with cardiac
disease carries much lower survival rates. An ELSO registry study
showed that overall ECMO survival is 45% in children with
cardiac disease, but drops down to 23–25% survival for ECMO
between 14 and 28 days, and 13% for ECMO runs longer than 28
days (40).
SUPPORTIVE CARE
The Extracorporeal Life Support Organization (ELSO) regularly
publishes informative and updated guidelines on pediatric
and neonatal cardiac ECMO including supportive care (33).
Anticoagulation during neonatal cardiac ECMO is essential and
can be very challenging, although it is beyond the scope of this
review. In this review, we restrict ourselves to a few important
issues specific to neonatal cardiac ECMO. For more information
on supportive care (e.g., infections, temperature management,
analgesia, and sedation), we refer to the ELSO guidelines and
ELSO “Red book” (33, 59).
Echocardiography
The role of echocardiography in cardiac ECMO is essential
in assessing ECMO initiation and separation readiness,
cannula positions, and the development of complications
such as ventricular dilatation or cardiac tamponade, but also
has important limitations as physiological changes induced
by ECMO may alter echocardiographic findings (55). An
echocardiography-trained physician should be part of the team
caring for neonates and children on ECMO, and the use of
specific and consistent echocardiographic protocols for patients
on ECMO is recommended (55).
Mechanical Ventilation
Generally, neonates who receive cardiac ECMO have healthy
lungs and have not received high ventilation pressures for
prolonged periods of time prior to ECMO initiation. Also,
relatively short ECMO duration of 5–7 days is expected for
these patients. The goal of mechanical ventilation during
ECMO is to minimize lung injury and to optimize lung
function in order to allow separation from ECMO once
myocardial recovery has occurred (33). Therefore, most often,
low ventilation pressures can be used during ECMO aimed at
maintaining normal tidal volumes (4–6 ml/kg) and preventing
alveolar collapse by using PEEP of 8–10 cm H2O. No single
ventilation strategy is universally practiced, and the suggested
target may be inappropriate in patients with an open sternum,
poor lung compliance, pulmonary hemorrhage, or intrathoracic
hematoma (33). Some neonates, however, may have atelectasis
which may require inhalation therapy, physical therapy, and/or
bronchoscopy as it is essential to keep the lung open. Therapy
resistant atelectasis can be due to tracheal and/or bronchial
compression by cardiac or vascular structures which might
require contrast CT-scanning to identify.
In neonates with an open sternum, lower ventilator pressures
will often suffice unless there is blood or fluid in the thoracic
space which should be considered for removal or drainage.
Cardiopulmonary bypass and its extension to ECMO have been
shown to cause a decrease in lung compliance through reduction
in the surfactant activity and surfactant has recently been used
safely and effectively in neonatal cardiac ECMO patients with
decreased lung compliance (60).
SINGLE VENTRICLE LESIONS
Extracorporeal support in neonatal patients with single-ventricle
physiology is particularly challenging, but also represents a
growing and substantial group of neonates who are being
supported by ECMO worldwide. Following the stage-one
operation for hypoplastic left heart syndrome, 13–20% of
neonates will receive ECMO support (8, 61, 62).
General risk factors for requiring ECMO post-stage-one
surgery are similar to other post-cardiotomy risk factors, such
as low birthweight and longer CPB-time. More specific risk
factors include a small ascending aorta (<2mm), mitral stenosis
with aortic atresia, intraoperative shunt revision, and a right
ventricular to pulmonary artery shunt (RVPAs) when compared
with a modified Blalock-Taussig shunt (mBTs) (62, 63). In the
single-ventricle reconstruction (SVR) trial, most neonates who
received ECMO post-stage one (70%) failed to separate from
CPB and had significantly lower transplant-free survival rates
compared to neonates not receiving ECMO post-Norwood (62).
In single-center study by Hoskote et al., 56% of post-operative
single-ventricle ECMO patients received ECMO because of
cardiac arrest, and 44% because of LCOS, with 44% survival
to discharge (64). The indication for initiation of ECMO also
significantly impacts survival. In a single-center study in 44
neonates, patients cannulated for hypoxemia, and particularly
shunt thrombosis, had markedly improved survival (72%)
Frontiers in Pediatrics | www.frontiersin.org 7 August 2019 | Volume 7 | Article 327
Roeleveld and Mendonca Neonatal Cardiac ECMO 2019
FIGURE 2 | ECMO cannulation and preferential ECMO flows in single-ventricle patients with BT-shunt (A, left) or Sano-shunt (B, right). In both diagrams (A, B), the
arterial cannula is placed in the neoaorta, but it can also be placed through the carotid artery or in the innominate artery. RCCA, right common carotid artery; LCCA,
left common carotid artery; LSA, left subclavian artery; RSA, right subclavian artery; IA, innominate artery; RPAs, right pulmonary arteries; LPAs, left pulmonary
arteries; MPA, main pulmonary artery; SVC, superior vena cava; IVC, inferior vena cava; RA, right atrium; LA, left atrium; RCA, right coronary artery; LCA, left coronary
artery; RV, right ventricle; LV, left ventricle. Drawings by Marta Velia Antonini.
compared to those supported primarily for low cardiac output
(21%) (65).
Without going into the complete debate about mBTs vs.
RVPAs, which is out of the scope of this review, there is an
important difference between the two shunts regarding ECMO
management. In the SVR trial, after adjusting for surgeon and
birth weight, neonates with a mBTs had smaller chances of
receiving ECMO and had significantly better outcome after
ECPR or ECMO compared to neonates with a RVPAs (62). Let’s
take a closer look at ECMO management in those two specific
physiologies (Figure 2).
ECMO and mBTs
Because of the position of the arterial cannula relative to
the mBTs and the lower vascular resistance in the pulmonary
circulation relative to the systemic circulation, a large proportion
of ECMO blood flow will be directed toward the pulmonary
circulation, leading to underperfusion of the systemic circulation.
In the past, attempts were often undertaken to partially
or completely close the mBTs while on ECMO to improve
systemic blood flow. That approach of “clipping the shunt,”
however, has been shown to increase mortality due to
obstruction in the shunt or in the pulmonary vasculature
after decannulation and has largely been abandoned in favor
of increasing ECMO flow to desirable systemic blood flow,
while accepting a significant amount of pulmonary blood
flow (26, 66). We therefore recommend a higher blood flow
(up to 200 ml/kg/min).
ECMO and RVPAs
In neonates with an RVPAs, the arterial ECMO cannula is
positioned after the source of pulmonary blood flow. This means
that if there is no pulsatility of the heart itself, there will be no
pulmonary blood flow at all, which leads to the risk of clotting the
shunt and/or the pulmonary vasculature. In neonates with some
degree of pulsatility, there will be pulmonary blood flow which is
dependent on pre-load of the right ventricle (RV) and pulmonary
vascular resistance. In that scenario, increasing ECMO flows will
lead to decreased pre-load as the drainage cannula will empty the
RV and decrease pulmonary blood flow, with the possible risk of
thrombosis of the shunt or even the RV. And absent pulmonary
flow might lead to increased mortality similar to mBTs patients
with clipped shunts (26). All in all, in neonates with an RVPAs,
we recommend not to use high flows as in mBTS patients, but
to titrate the flow as low as possible to achieve adequate systemic
blood flow and also some degree of pulmonary blood flow over
the RVPAs. It might be necessary to use some inotropes to
promote contractility in this specific group of patients.
Survival to discharge in hypoplastic left heart patients
supported by ECMOwas 31% as shown in an ELSO registry study
by Sherwin et al. (67). Predictors of mortality were pre-ECMO
ventilation > 5 days (OR 1.9), pre-ECMO PEEP > 8 (OR 1.9),
and increased ECMO duration. In a separate single-center study,
survival was 62% and failure to clear lactate within 24 h was also
a significant predictor of mortality (45).
A specific group are patients post-hybrid palliation of HLHS.
In an ELSO registry study, survival to discharge was only
16% in neonates who received ECMO following stage 1 hybrid
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palliation (68). This could be because, in many centers, hybrid
palliation is reserved for high risk patients, but also could be
due to cannulation challenges, and risk of stent compression or
even occlusion.
Of concern is late attrition following ECMO in SV survivors.
Although incidence is low, mortality is very high (69). Neonates
who survive to discharge following ECMO post-Norwood have
been shown to have an increased risk of death or cardiac
transplant, when compared to patients who did not receive
ECMO post-Norwood (45, 61, 63, 70).
For respiratory failure in SV patients, VV ECMO can also be
considered as an option with good outcomes (71, 72). In an ELSO
registry study of 89 patients with single-ventricle physiology and
a median age of 66 days overall survival was 51% for respiratory
indications which included neonates as young as 9 days (71).
The most common cannulation approach for patients who were
unrepaired or palliated with a central or Sano shunt was a
double-lumen venous cannula in the right internal jugular vein.
Advantages could be preservation of pulsatile flow and
decreased afterload on the heart, as well as avoiding cannulation
of the carotid artery which precludes potential run-off through
a systemic-to-pulmonary shunt. For more in-depth information
on cannulation strategies, timing, circuit flow, and lung rest
strategies we refer you to an excellent review by Nair and Oishi
from 2016 (72).
WEANING
In adults, end-tidal CO2 (etCO2) has been shown to be a useful
continuous parameter for predicting the adequate timing of
weaning of ECMO for circulatory failure at the bedside (73).
Many physicians dealing with neonates also use etCO2 as it can
indicate increasing pulmonary blood flow as a sign of increased
intrinsic right ventricular output due to a healing myocardium or
decreasing pulmonary vascular resistance. There is however no
known cut-off etCO2 when a neonate might successfully separate
from ECMO, therefore it can merely be used as an indirect
indication of ongoing recovery.
When weaning is not successful and additional time does not
lead to adequate recovery, it is important to consider possible
transplantation or withdrawal of support and shift attention to
comfort of the neonate and guidance for the parents.
Survival to decannulation in neonatal cardiac ECMO is
71%, but drops down to 49% when it comes to hospital
discharge or transfer (1). Often, ECMO support is removed
during a still fragile state of the patient’s recovery. Timing
and manner of weaning support highly affect the chances of
survival. Unfortunately, up to this date, very little evidence has
been published to help identifying parameters which predict
readiness to be separated from ECMO. Recommendations about
the speed of weaning or acceptable amount of inotropic support
are also lacking.
The reason of myocardial dysfunction is a relevant factor for
the expected time to recovery and removal of ECMO. Recovery
from cardiac dysfunction post-cardiac surgery is expected to
happen between 48 and 72 h after initiation of ECMO. The
absence of signs of recovery, such as increasing pulse pressure or
increasing end-tidal pCO2 after that period, should lead instantly
to further assessment of remaining cardiac lesions if not already
done so (44).
Recovery from a primary myocardial dysfunction, as with
myocarditis, occurs over weeks or months, in some cases not at
all. Transition to a VAD device as bridge to recovery or bridge to
transplant need to be taken into consideration if no evidence of
myocardial recovery has occurred within 2 weeks (74).
Weaning can be started with signs of myocardial recovery
and adequate resolution of systemic inflammatory response or
pulmonary problems (75).
Cardiac function assessment by echocardiography during full
ECMO flow does not predict performance of the heart under the
completely different circumstances occurring after decannulation
(which will be increased preload and decreased afterload) and
might only be used as a trend.
Echocardiography under low flow conditions has been shown
as being predictive of successful decannulation in adult patients
with cardiogenic shock (76).
However, achieving actual low flow conditions in neonates is
not possible due to the required minimal flows of the ECMO
devices (100–200 ml/min). Therefore, different techniques of
weaning trial in which the readiness for separation from ECMO
can be assessed (pulse pressure, blood pressure, inotropic needs,
echocardiography) are practiced in this age group. In patients
with a left-sided drainage cannula, this must be clamped and/or
removed allowing restoration of LV pre-load before assessing
weaning readiness.
A common approach of weaning ECMO flows in neonates
includes inserting a connection (“Bridge”) between the arterial
and venous limb (arterio-venous bridge) of the ECMO circuit.
This allows to clamp access to the patient, while there remains
continuation of flow in the ECMO circuit. The patient and the
circuit are isolated from each other. Now the hemodynamics
such as blood pressure, CVP, lactate, as well as the demand of
inotropic support to remain off circuit, can be assessed and an
echocardiography should be performed. This method introduces
areas of stagnant blood in stop cocks and the cannulas, with the
subsequent risk of clot formation in the ECMO circuit. Most
centers flush the cannulas every 10min and limit this kind of trial
off period to around 2 h (59).
Other groups promote trial off with retrograde pump flow of
the ECMO circuit (77, 78). During this approach, revolutions
per minute (RPM) are lowered until the patient’s arterial blood
pressure is slightly higher than the post-oxygenator pressure,
which results in reversal of the flow. The ECMO circuit
becomes an arterio-venous shunt and the patient does not
receive circulatory or respiratory support. The advantage of this
method is that it has no stagnant blood flow in the cannula
and that it places an additional burden on the cardiac output,
which therefore reassures of sufficient myocardial function.
Not observed or investigated by the groups who practice this
approach is the theoretical risk of flushing debris and clots
absorbed in the oxygenator with the retrograde flow back into the
patient. Further research must be established to further evaluate
the risk.
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Once readiness to be separated from ECMO is established,
the process of decannulation can take place. This includes the
optimization of conditions with low dose inotropic support
started early enough to reach the patient, lung recruitment,
correction of metabolic abnormalities, and attaching pacing
wires to the pacemaker ensuring proper function of them.
Furthermore, each patient should have a defined plan in place
in the event of clinical deterioration after decannulation and
weather reinstitution of ECMO is an option.
Decannulation for neonatal cardiac ECMO is done surgically
and can be performed either in the ICU or in the operating
room. Neck cannulation often leads to vessel reconstruction
and the cannulation sites must be investigated carefully for any
damage, whichmight need extended repair, such as carotid artery
dissection (36). Furthermore, Di Gennaro et al. published a
study showing increased risk of stroke in patients with carotid
cannulation (79).
Weaning and decannulation of patients with systemic to
pulmonary shunts, which are partially or completely clamped
is different. In those cases, readiness to wean must be assessed
without decreasing flows as this would lead to desaturations.
Separating from ECMO is a complex process and




Circuit technology has greatly advanced over the years, but
neonates do deserve some special considerations which are nicely
reviewed by Connelly and Blinman (80). Nowadays, most centers
have moved from roller pumps to modern centrifugal pumps
(81). Detailed discussion of the ECMO circuit is beyond the
scope of this review but there are some important issues to
consider. First, the relatively large priming volumes for neonates
can introduce fluid shifts and can have a pharmacological impact.
Second, the relatively low blood flows can make neonates more
prone to (circuit) thrombosis and more difficult to wean. And
third, in the small neonate accurate cannula position can be
more precarious than in larger children or adults, especially in
veno-venous double-lumen cannulas.
MID AND LONGTERM OUTCOMES
Neonates surviving cardiac ECMO remain at risk of ongoing
health problems, unplanned cardiac interventions, unplanned
rehospitalization, neurodevelopmental problems, lower mental
scores, language acquisition delays, behavioral problems, and
diminished quality of life compared to healthy children, children
with chronic conditions, and children with congenital heart
disease who did not receive ECMO (82–86).
To gain better insight in these mid and long-term outcomes,
protocolized follow-up is important, with the aim of identifying
neurodevelopmental delay. Hopefully, by focusing on the future
development of these patients and sharing outcomes and
interventions through research, the ECMO community can
develop interventions aimed at minimizing ongoing health issues
and optimizing quality of life for patients and their families after
hospital discharge.
FUTURE (RESEARCH)
In neonatal cardiac ECMO, one must face many challenges
which are common to almost all neonatal and pediatric
ECMO patients, such as infection control and anticoagulation.
Exciting developments are being made regarding ECMO
anticoagulation, in which attempts are being made to
anticoagulate the circuit (rather than the patient) by using
nitric-oxide donors in the ECMO tubing (87). The balance
between bleeding of the neonate and thrombosis of the circuit
remains very delicate, especially in neonates with still developing
hemostasis in whom the correlation of coagulation tests with
the level of anticoagulant and clinical outcomes remains
poor (88).
Other important steps that need to be achieved are related
to identifying the right patient and the right time for ECMO.
Attempts are being made to develop prediction scores, but,
at the moment, these remain restricted to pulmonary ECMO
and adult cardiac ECMO (89–92)1. No prediction scores exist
as of yet for neonatal cardiac ECMO. Hopefully, by gathering
more data from large databases such as ELSO or the STS-
database, and by performing large multicenter trials, prediction
scores can be developed in the future. However, due to
the relatively small number of neonatal ECMO patients and
many aggregating factors, this will be a challenging task, and
identifying “the perfect ECMO candidate” will probably remain
a local team decision based on experience and published results
of others.
Pharmacodynamic and distribution studies are also needed
in this very special group of patients. Neonates with their
immature organ function, fast changes in maturation (ontogeny)
and significantly increased distribution volume on ECMO, plus
unknown absorption in the circuit components, are extremely
challenging to manage for adequate medication levels. As
mentioned before, research directed on long-term outcomes and
quality of life are essential. Not only will they help at early patient
intervention, but they can also teach the ECMO community
the limitations of ECMO support and will help in deciding to
which patients we should offer ECMO and to which patients we
should not.
CONCLUSIONS
Extracorporeal Membrane Oxygenation (ECMO) is an
invaluable tool for neonates with therapy resistant circulatory
failure. Patient selection and timing of ECMO initiation however
remain very difficult and is not yet evidence based. Mortality
is very much dependent on underlying diagnosis, the ability
to provide adequate systemic blood flow, duration of ECMO
support and concomitant adverse events and complications.
Therefore, after ECMO initiation, attempts should be made
1http://www.picuscientist.org/pprep
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as soon as possible to identify concomitant problems whose
solution would improve the outcome, such as residual lesions
following cardiac surgery or arrhythmias. By adequately
addressing those underlying issues and limiting the time
on ECMO, preferably <7 days, while resting the heart as
much as possible, mortality can be reduced. In non-surgical
heart disease, restoration of adequate myocardial function
can take longer, sometimes requiring ECMO support up
to 2 or 3 weeks.
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